ReviewCancers2020
Clinical Management of Diffuse Low-Grade Gliomas.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review.Journal of neuro-oncology · 2023Pooled it
- A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.Neuro-oncology · 2024Trial
- Early-Onset Medullocervical Low-Grade Glioma With FGFR1 Mutation and Leptomeningeal Spread in an Infant: A Case Report.Clinical case reports · 2026Article
- Estimating temporal treatment-effect patterns of radiotherapy and chemotherapy in lower-grade gliomas using causal machine learning.Scientific reports · 2026Article
- Impact of postoperative blood pressure management on postoperative hemorrhage after resection of intraparenchymal brain tumors.Acta neurochirurgica · 2026Article
- Radiographic Enhancing Progression Without Molecular or Histologic Progression in IDH-Mutant Grade 2 Astrocytoma Treated With an IDH Inhibitor: A Case Report.Case reports in neurological medicine · 2026Article
- Integrated single-cell and bulk RNA-sequencing data reveal prognosis and therapeutic response in low-grade glioma based on hypoxia-lactylation related genes.Discover oncology · 2025Article
- Article
- Magnetic Resonance Imaging Radiomics-Driven Artificial Neural Network Model for Advanced Glioma Grading Assessment.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- A 5-Year Update on the Clinical Development of Cancer Cell-Based Vaccines for Glioblastoma Multiforme.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Multicellular Network-Informed Survival Model for Identification of Drug Targets of Gliomas.IEEE journal of biomedical and health informatics · 2025Article
- CDK5: Insights into its roles in diseases.Molecular biology reports · 2025Review
- Machine learning-based identification of histone deacetylase-associated prognostic factors and prognostic modeling for low-grade glioma.Discover oncology · 2024Article
- The role of postoperative blood pressure management in early postoperative hemorrhage in awake craniotomy glioma patients.Neurosurgical review · 2024Article
- Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response.Scientific reports · 2024Article
- Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a Combination of Radiotherapy and Immunotherapy in Glioma Patients.International journal of molecular sciences · 2024Article
- Glioblastoma vaccines: past, present, and opportunities.EBioMedicine · 2024Review
- Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know.Radiology. Imaging cancer · 2023Review
- A novel, effective machine learning-based RNA editing profile for predicting the prognosis of lower-grade gliomas.Heliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse low-grade gliomas (LGG) represent a heterogeneous group of primary brain tumors arising from supporting glial cells and usually affecting young adults. Advances in the knowledge of molecular profile of these tumors, including mutations in the isocitrate dehydrogenase genes, or 1p/19q codeletion, and in neuroradiological techniques have contributed to the diagnosis, prognostic stratification, and follow-up of these tumors. Optimal post-operative management of LGG is still controversial, though radiation therapy and chemotherapy remain the optimal treatments after surgical resection in selected patients. In this review, we report the most important and recent research on clinical and molecular features, new neuroradiological techniques, the different therapeutic modalities, and new opportunities for personalized targeted therapy and supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.